All In Biotech

Drug Trial Radar · NCT06049342

A Trial to Evaluate the Safety, Tolerability, and Efficacy of NCR100 Injection in the Treatment of Subjects With KOA

A Phase I, Open Label, Single Arm, Multiple Center, Dose Escalation Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Human Induced Pluripotent Stem Cell Derived Mesenchymal Stromal Cells (NCR100) Injection in the Treatment of Subjects With Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Jan 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

12

Planned (sponsor's estimate)

Start

Jan 25, 2024

Primary completion

Jun 2024

Study completion May 2025

Sponsor

Sponsor type
Industry
Collaborators
Shanghai 6th People's Hospital; Beijing Luhe Hospital
First posted
Sep 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It is a dose-escalating, open label study in adult KOA subjects.

Conditions

  • Knee Osteoarthritis

Interventions

  • NCR100 injectionBiological

    Subjects will receive a one-dose intra-articular NCR100 injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Event(AE) or Serious Adverse Event(SAE)Time frame: Week1,Week2,Week4
  2. Dose-Limiting Toxicity(DLT)Time frame: 4 weeks after injection

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.